Purpose: Determine the impact of anti-epileptic drugs (AED) for drug resistant patients with idiopathic generalised epilepsy. Methods: A systematic search of Medline, Cumulative Index to Nursing an Allied Health Literature (CINAHL), Cochrane Epilepsy Group Central Specialised Register, Cochrane Central Register of controlled Trials (CENTRAL), Embase and Lenus was performed. Nine randomised controlled trials were included. All trials compared antiepileptic drugs to placebo. Outcome measures assessed were 50% or greater reduction in seizure, seizure freedom and adverse events. Results: Seven trials report a 50% or greater reduction in seizure frequency. This was statistically significant (p = <0.00001) with a narrow confidence interval implying that the overall this meta-analysis has reasonable power to detect an effect. It demonstrated a significant statistical difference of seizure freedom occurring in the drug treatment group compared to placebo. Adverse events were identified with each drug and are reported. There were however methodological issues with the trials included. Quality appraisal was undertaken using the risk of bias assessment from Rev Man 5.3 tool for all randomised controlled trials retrieved.
Introduction
Epilepsy is one of the most common neurological conditions affecting 70 million people worldwide [1] , with an incidence of 36,000 in Ireland [2] . More than half of patients will achieve seizure control. Approximately 30% of patients will remain drug resistant [3] . Drug resistant epilepsy is defined by the International League Against Epilepsy (ILAE) as a failure of adequate trials of two tolerated, appropriately chosen anticonvulsant drugs, whether as monotherapy or in combination, to achieve sustained seizure freedom [4] . Patients who have drug resistant epilepsy are at increased risk of premature death, injuries and psychosocial issues [5] . Societal costs are significant as individuals with drug resistant seizures make up a third of the epilepsy population [1] .
Reasons for drug resistant epilepsy are likely to be multifactorial. Overuse of multidrug efflux transporters at the epileptic focus causes a decrease of intracerebral drug concentration [5] . Negative influences for seizure remission must also be considered. This includes history of status epilepticus, number of failed drug therapies, total number of tonic-clonic seizures, neurological insult, duration of epilepsy and developmental disability [6] . Patients need to be informed of the risks associated with drug resistant seizures including Sudden Unexpected Death in Epilepsy (SUDEP). SUDEP denotes the main cause of death in patients with drug resistant epilepsy [5] .
Idiopathic generalised epilepsy (IGE) is a common form of epilepsy representing 20-40% of all epilepsies. Idiopathic is defined as epilepsy of largely genetic or presumed genetic origin with no neuroanatomical or neuropathological abnormality [7] . Seizure types in IGE include myoclonic, absence and generalised tonic clonic seizures [7] . Patients with IGE usually have normal intelligence, normal neurological examination and it is common in both sexes and all races [8] . On electroencephalography (EEG), IGE is characterised by a 3 Hz spike and wave discharge or rapid (>3 Hertz) spike and wave discharge [9] . These discharges are often precipitated by hyperventilation, sleep deprivation and intermittent photic stimulation. In spite of the view that IGE and its related seizures are easily treated, research has shown that approximately 35-40% of patients with IGE syndromes do not achieve long term seizure remission [10, 11] . Of all the seizure types, primary generalised tonic clonic (PGTC) seizures are the most serious and are a known risk for SUDEP [12, 13] . Furthermore, co-morbidities such as cognitive impairment and psychiatric disorders are recognised in those with drug-resistant epilepsy [14] . Therefore, safer and far more effective drugs are required for these patients.
Anti epileptic drugs are the cornerstones of therapy in IGE. There are very few licensed (AED) to treat IGE. Valproate is widely used as a first line treatment in IGE. However, this is primarily anecdotal based only on individual case reports and case series and not on class one or two randomised controlled trials. There is reasonable efficacy data in patients with childhood absence epilepsy treated with ethosuximide and valproate [15, 16] . Valproate is a very effective AED for many of the seizures associated with IGE ie. PGTC, myoclonic and absence seizures. National Institute for Health and Care Excellence (NICE) guidelines recommend it should remain the first choice for male patients with generalized epilepsy [15, 17] . However, there are some patients that do not respond to this agent and other patients where valproate presents some risk of therapy. For example, for women of childbearing years, valproate is associated with dose related teratogenicity higher than any other AED on the market [17] . Risks are higher than 30% in women taking doses greater than 1100 mg/day [18] . Lamotrigine, levetiracetam, topiramate, zonisamide and perampanel have demonstrated efficacy for a broad spectrum of seizure types including IGE [19, 20, 21, 22, 23, 24] . However, clinicians must be aware of the risk of exacerbating seizures. If juvenile myoclonic epilepsy (JME) is suspected lamotrigine is not recommended as it may exacerbate myoclonus. Moreover, carbamazepine or oxycarbazepine may exacerbate myoclonus or absence seizures [17] .
The efficacy of AED treatment is guided by clinical trials and clinical experience. The best studies are randomised, blinded and prospective controlled trials that can offer good recommendations. It is one of the most scientifically rigorous methods of testing hypothesis [25] . A dearth of RCT's exists that evaluate the efficacy of AED treatment in partial epilepsies; however there are very few trials for IGE. Large, randomized controlled trials designed to provide class one or two evidence, face a number of recruitment hurdles in IGE. This may be due to the fact that most clinical trials address seizures, not syndrome which can cause constraints. Trials for absence and myoclonic seizures have strict clinical and EEG criteria. PGTC seizures trials may be contaminated by patients with secondary generalised tonic clonic seizures. In addition, patients with IGE are often controlled on monotherapy so it may be difficult to find adequate patient numbers for the well-designed trials making recruitment a challenge.
A gap in the literature exists pertaining to evidence of drug treatments options available for drug resistant patients with IGE and existing options are based on small scale studies. Between 35-40% of patients with IGE are poorly controlled [10] . It is crucial that clinical decisions are made on rigorous evidence from well controlled drug trials for the treatment of this patient group.
The purpose of this systematic review is to explore the following research question: what is the impact of anti-epileptic drugs for all patients with drug resistant IGE? The aim was to review the available rigorous evidence of the effects of the various drug treatments options for patients with IGE. Our objectives were to systematically collect, critically appraise and synthesize evidence regarding the efficacy and tolerability data from existing trials comparing AED for all patients with drug resistant IGE.
Methods
Outcomes are presented in terms of primary and secondary outcomes. The primary outcome is to determine the percentage of patients with a greater than 50% reduction in seizures. The secondary outcomes determined the proportion of patients who become seizure free and adverse events. Inclusion criteria that generated from the research question were all vivo studies, all drug resistant patients of any gender or ethnic background. Patients included required a confirmed diagnosis of IGE in accordance with ILAE classification (1989) . All studies included were RCTs of AED's compared with each other or placebo and had baseline seizure data recorded only. Studies with the following characteristics were excluded: non-human data, patients with focal seizures, symptomatic generalised epilepsy, intellectual disability or Lennox Gastaut. Patients who had an abnormal or lesional MRI and normal EEG were excluded and all studies not published in English.
Search strategy
The following databases were searched: Medline, Cumulative Index to Nursing an Allied Health Literature (CINAHL), Cochrane Epilepsy Group Central Specialised Register, Cochrane Central Register of controlled Trials (CENTRAL), Embase and Lenus.
The following MeSH terms were used: Epilepsy; Generalised, Myoclonic, Anticonvulsants, Valproic acid. Keywords included: Primary generalised epilepsy; primary generalised seizure; myoclonic epilepsy; myoclonic seizure; absence seizure; tonic clonic seizure; tonic-clonic seizure; idiopathic generalised epilepsy; drug/drugs; zonisamide; perampanel; levetiracteam; lamotrigine; topiramate; sodium valproate; randomised controlled trial or placebo; focal or partial. In addition to searching the databases; the reference lists of chosen articles were also reviewed and four relevant articles were retrieved.
Data extraction and management
Data from included studies was extracted with reference to authors, publication year, centres, title, duration of study, geographical location, sample size, participants, study methodology, outcome measures, results and follow up data. All the relevant extracted data was transferred into the Cochrane Collaboration's software programme, Review Manager 5.3 [26] and this was checked by the second reviewer. The articles were summarized narratively, giving an overview of study design, geographical location, participants, sample sizes and a description of interventions under investigation.
Quality appraisal
Two review authors assessed the risk of bias of each trial. Quality appraisal was undertaken using the risk of bias assessment from the Review Manager 5.3 tool as all retrieved studies were RCT's [26] .
Data analysis and synthesis
Data was analyzed in accordance with the Cochrane handbook for systematic reviews of interventions [27] . We analysed dichotomous data in terms of RR for each trials with uncertainty in each trial expressed by the use of 95% confidence interval (CI). Methods Randomized double blinded placebo controlled, parallel group multicentre add on study of gabapentin in generalized seizures. It became evident that a number of people enrolled who had a high probability of having partial epilepsy or SGE. Therefore, a second analysis as conducted excluding data for patients who had partial seizures, localized cerebral pathology on imaging or an identified etiology consistent with partial epilepsy. This evaluable patient analysis thus included data only for patients with probable IGE. Participants 64 in efficacy analysis, mean age 30.
Interventions Gabapentin versus placebo Outcomes
Primary outcome was the reduction in the frequency of GTCS, the primary efficacy variable was responder rate defined as the percentage of patients with at least a 50% reduction in the seizure frequency during the treatment period as compared with baseline. Other outcome is reduction in the frequency of other generalised seizures types. Adverse events.
Bias

Authors' judgement
Support for judgement
Other bias High risk The failure to achieve statistical significance may be due to the small number of patients contributing data. In addition a low dose of GBT used which may contribute to findings.
French et al. 2015
Methods Double blind randomised placebo controlled paralleled group study to compare perampanel treatment to placebo for tonic clonic seizures in idiopathic generalized epilepsy. Prior to combining data for analysis, the presence and extent of clinical heterogeneity between trials was considered carefully. A clinical judgement was made about whether it was reasonable to combine studies together based on whether individual studies differed considerably in populations, intervention, comparison and outcomes. Each study compared different interventions and had variable populations. However, of the nine trials included three of the interventions were similar, lamotrigine, levetiracetam and topiramate. The statistical validity of combining the trials together assessed for homogeneity of the outcomes of the studies. For the remaining trials dichotomous data were analysed and presented individually [24, 28, 29] in terms of Risk Ratio (RR).
Results
Search strategy results
The systematic search retrieved a total of 364 studies, four of which were identified through the reference list of articles screened. Two review authors independently assessed titles of all papers for eligibility. After duplicates were removed, the titles and abstracts of the 325 articles were screened. Following full text review of the remaining 25 studies, nine trials met the inclusion criteria [19, 20, 21, 22, 23, 24, 28, 29, 30] . Table 1 summarizes the characteristics of the included trials. Reasons for exclusion were trials including patients with symptomatic generalised epilepsy [31, 32] , seizures other than generalised onset or unclassified seizures. In addition trials that did not measure specified outcome measures, conference abstracts and monotherapy trials were excluded [33, 34] .This search strategy is summarized in the prisma flow chart below (Fig. 1). 
Participants and sample size
The nine trials consisted of a total of 921 participants. The mean age in all trials was 25.4 years of age. Four of the trials included a total 106 children, <16 years of age [20] ; 2-12 years of age [21] ; <16 years of age [19] and (2-12 years of age) [24] . There was a wide variation in sample sizes with the perampanel RCT [23] and levetiracetam RCT [19] , having more than double the topiramate RCT [20] . The smallest sample sizes were the open label experience of topiramate which had 12 patients [28] and the subgroup of children and adolescents (n = 45) that were analysed [29] .
The nine trials investigated AED's included patients with all primary generalised seizure types [28] , PGTC seizures [19, 20, 21, 22, 23, 24, 29] and myoclonic seizures [30] . However, there were a number of patients included in the trials who had seizures not typical of IGE [19, 20, 21, 28, 29] .
All patients had a diagnosis of IGE. Both levetiracetam studies recruited drug resistant patients with a confirmed diagnosis of IGE [19, 30] . However, there was no standardization between centres for syndrome diagnosis [19, 30] . Principal investigators were certified neurologists and epileptologist and diagnosis was based on clinical and EEG features in accordance with the ILAE 1989 diagnosis [19, 30] . The perampanel RCT had strict guidelines in terms of inclusion criteria for the trial [23] . Patients were considered ineligible if they had insufficient data to confirm a diagnosis of IGE, eg. PGTC seizure but had a normal EEG [23] . Conversely, 33% (n = 39) of patients were included in the lamotrigine trial whom had no generalised discharges on EEG [21] . Baseline PGTC seizure per month was much higher in the topiramate trial [20] indicating that trial populations may differ further.
Geographical location
In terms of the geographical location of the studies, all trials were worldwide multicentre except the topiramate trial which reported patients from one centre in an open label extension of a prior multicentre trial [28] . Three trials were carried out in the United States of America and Latin America [20, 21, 24] . The largest multicentre trials were the perampanel trial [23] (78 centres worldwide) and levetiracetam trial [19] (50 centres worldwide) having 164 participants in each trial.
Study designs
All trials were randomised placebo controlled trials where the placebo arm continued their baseline AED's throughout the trial except in the topiramate trial where concomitant AED was withdrawn or dosage reduced during the open label topiramate treatment phase [28] . All trials were parallel arms and not cross over trials. Study design was similar with the exception of the perampanel trial [23] , which allowed for 1-3 AEDs at baseline while the rest had 1-2 AEDs at baseline. The number of concomitant AED's is not reported in the open labelled experience of topiramate [28] . Both of the levetiracetam trials [19, 30] and the perampanel trial [23] had shorter titration periods of 4 weeks. However, the gabapentin trial had the shortest titration over 2 weeks [29] . The levetiracetam trial had the longest maintenance period of twenty weeks [19] .
Interventions and follow up
The nine trials investigated different AED's against placebo, levetiracetam versus placebo [19, 30] , lamotrigine versus placebo [21, 24] , lamotrigine XR versus placebo [22] , topiramate versus placebo [20, 28] , perampanel versus placebo [23] and gabapentin versus placebo [29] .
In terms of the evaluation period, the levetiractam trial had the longest period of twenty weeks [19] and the shortest been the topiramate open label experience which was eight weeks [28] . The remaining trials were twelve weeks [20, 21, 22, 24, 29, 30] , and thirteen weeks [23] . Five of the studies reported losses to follow up [19, 20, 21, 22, 23] . Biton and colleagues report losses of sixteen lamotrigine subjects and fourteen placebo [21] . It is unclear how these participants were handled in the efficacy analysis.
Quality appraisal of included studies
Quality appraisal was undertaken using the risk of bias assessment from Rev Man 5.3 tool for all RCT's retrieved [30] .
3.6.1. Allocation 3.6.1.1. Random sequence generation. There was no explicit statement of methods of randomisation used to generate allocation sequence in four of the studies [21, 22, 28, 29] . Randomisation sequence was demonstrated in the remaining studies [19, 20, 23, 24, 30] .
3.6.1.2. Allocation concealment. Methods used for concealing the group allocation were unclear in all trials.
Blinding
In terms of performance bias, blinding of participants and personnel was evident in four studies [19, 20, 23, 30] . Blinding was unclear in the remaining studies, with two of these reported as blinded, however no actual description of the blinding process was given [24, 29] . With regard to detection bias, treatment identity was kept by the central randomisation centrec [19] , investigators and study monitors remained blinded in two trials [20, 23] , and therefore it is unlikely that blinding could have been broken. Blinding of outcome assessment was unclear in remaining included studies [21, 22, 24, 28, 29, 30 ].
Incomplete outcome data
Outcome data reporting was completed in eight trialsc [19, 20, 21, 22, 23, 24, 28, 30] . Analysis was performed for all the intention to treat (ITT) population who took at least one dose of the study medication. In the lamotrigine trial they report losses of 16 lamotrigine subjects and 14 placebo participants [21] . It is unspecified how these participants were handled in the efficacy analysis however; given that all subjects that were given at least one dose were included it is likely that the last observation carried forward approach was used.
Selective reporting
Seven trials reported information on the outcomes of interest in their studies which means there is a low risk of reporting bias [35] . However, not all data was reported for all trials. Two trials did not report all secondary efficacy endpoints, !50% reduction in PGTCS seizure frequency [24, 29] and seizure freedom [29] . This increases the risk of bias in these studies [35] .
Publication and related biases
Trials produce positive results are more likely to be published than ones that have negative findingsc [35] . In our systematic review, despite a thorough and systematic search, only trials in the English language were included and may therefore decrease the precision of the summary effect implying a risk of publication bias. Sponsorship bias refers to the tendency of a scientific study to support the interests of the study's sponsor [35] . Three of the included studies acknowledged that funding was provided by drug companies [19, 22, 23] .
Effects of interventions/Results of outcomes of interest for this SR
All studies were analysed in terms of outcomes reported; !50% reduction in seizures, seizure freedom and adverse effects.
Primary outcome
Percentage of patients with !50% reduction in seizures
Seven of the nine included randomised controlled trials showed a !50% reduction in seizures [19, 20, 21, 22, 23, 28, 30] . A metaanalysis was carried out combining data from the six trials that presented their data [19, 20, 21, 22, 23, 30] (Fig. 2) . Three studies were not included in this analysis as they did not present the data for !50% seizure reduction [24, 28, 29] . Heterogeneity measures the variability in studies and is calculated as 1 2 = 36%. Forest plot 1 which shows that there is some degree of heterogeneity between the studies. A random effects model for meta-analysis is therefore used which takes into consideration the variability in the study populations or outcomes. Furthermore, it takes into account that there might be some studies unpublished or overlooked in the meta-analysis that would need to be considered in the future [37] . The overall effect was statistically significant (p = <0.00001) with the diamond not crossing the 'line of no effect'. Forest plot 1 illustrates that the greatest weight is attributed to the levetiacetam trial [19] (24%), followed by the lamotrigine trial [21] (21.3%) and perampanel trial [23] (20.5%). This suggests that these trials are closer to the 'true effect'. Overall, this meta-analysis suggests that there is an increased likelihood of patients experiencing a !50% reduction in seizures in the treatment groups.
Secondary outcome 4.2.1. Seizure freedom
In terms of the secondary outcome seizure freedom, a metaanalysis again was performed. Two studies were not included in this analysis [28, 29] . Firstly, one trial did not present the data for seizure freedom [29] and secondly, no control data was provided in another trial [28] . This meta-analysis demonstrated a SSD of seizure freedom occurring in the AED treatment group than placebo with an overall effect in terms of RR of 2.59. Fig. 3 (Forest plot 2) shows the black diamond does not cross the line of no effect indicating a SSD between the treatment and placebo groups (p < 0.00001). This was calculated again on a random effects model as it allows for variation in the effect among the populations studied [36] . In this meta-analysis the lamotrigine [22] and perampanel [23] trials had the greatest weight 22.9% [22] and 22.3% [23] , indicating rating closer to the 'true effect'. These studies also had one of the largest sample sizes which contribute to the overall findings of the analysis. Both the topiramate trial [20] and the levetiracetam trial [30] had a widest CI and weighed the least of all the studies. The wider the CI reflects small sample sizes in these studies which in turn represent less precision of the study results [36] .
Adverse effects
Adverse events are reported in all studies. TEAE were reported in 82.7% (n = 67) perampanel treated patients and 72% (n = 59) placebo treated patients. The majority of side effects reported were mild to moderate intensity however, in six perampanel treated patients the side effects were described as severe [23] . The most common adverse effects of treatment with perampanel reported (!10%) was dizziness, fatigue, headache, somnolence and irritability. The most serious TEAE's in the perampanel group were suicidal ideation in two patients which were possibly related to the drug and were withdrawn from treatment [23] . There were two deaths one case of SUDEP in the placebo group and one accidental drowning in the perampanel group. One patient in the perampanel group experienced status epilepticus but this resolved following discontinuation of perampanelc [23] .
TEAS's required discontinuation of treatment in 6.1% (n = 5) placebo treated patients and 11.1% (n = 9) perampanel treated patientsc [23] .Two patients in the perampanel group required discontinuation due to dizziness (n = 2) and vomiting (n = 2). Three placebo patients (n = 3) and five perampanel treated patients (n = 5) were discontinued due to psychiatric disorders. There was one case in the perampanel group which was a mild case of aggression, a moderate case of anxiety and insomnia and a severe case of abnormal behaviour, mood swings, suicidal ideation and suicidal attempt [23] . Dose adjustments were required due to adverse events in nine perampanel treated patients and six placebo group. All but one resolved on dose adjustment except for one case of dizziness in the perampanel group. One patient was withdrawn from the perampanel group following interruption of perampanel treatment due to aggression and vomiting [23] .
Adverse events that affected 10% or more of participants were reported in the topiramate trial 20 . The most common side effects experienced in the topiramate group were seasonal illness including upper respiratory tract infection 41% (n = 16) [20] . Central nervous system (CNS) side effects included somnolence 26% (n = 10), fatigue 18% (n = 7), difficulty with memory 13% (n = 5) and headache 13% (n = 5). Some CNS adverse events were reported more frequent in the topiramate group than the placebo group; somnolence, anorexia, difficulty with memory, nervousness, psychomotor slowing, fatigue and speech disorders and speech related problems. However, in the placebo group, headache dizziness, insomnia and personality disorder are reported more frequently [20] . Of note, 15% (n = 6) patients each reported anorexia and weight loss (n = 6) in the topiramate group [20] . Similarly, patients in the topiramate group experienced weight loss 41%, (n = 5), memory problems 8%, (n = 1), headache 8%, (n = 1), fatigue 8%, (n = 1) dizziness 8%, (n = 1) [28] . Lamortrigine was reported to be well tolerated in the trials [21, 22, 24] . Adverse events were reported in 22% (n = 13) of lamotrigine group and 10% (n = 6) of the placebo group [21] . Side effects that affected 5% of patients were reported [21] . 5% experienced dizziness (n = 3), 5% somnolence (n = 3), and 5% had nausea (n = 3) in the lamotrigine treatment group [21] . In contrast, 2% (n = 1), 2% (n = 1) and 3% (n = 2) of patients in the placebo group experienced these side effects respectively [21] . A total of 5% (n = 3) in the lamotrigine group and 2% (n = 1) in placebo group prematurely withdrew at the double blind phase due to adverse effects. Dizziness was also experienced by 6% (n = 4) of patients in the lamotrigine group in Biton and colleagues trial [22] .
Based on the data obtained a relative risk calculation of adverse events (dizziness, nausea, somnolence) was undertaken in Biton and colleagues study [21] . It showed a relative risk, ie. increased risk of 2.21, (95% CI 0.72-6.78) of these adverse events occurring in the lamotrigine group compared to placebo. Two of the studies had reports of a non serious rash [21, 22] . One patient reported an episode of urticaria one month after randomisation (n = 1) [21] and two patients withdrew due to rash (n = 2) in the lamotrigine group [22] . In both studies non serious rash was considered to be due to study medication.
Levetiracetam was reported to be well tolerated implying that few patients withdrew due to adverse effects during the treatment period; 1.3% (n = 1) levetiracetam group versus 4.8% (n = 4) placebo [19] . Nasopharyngitis was the most common adverse event in 13.9% (n = 11) of patients in this trial. This was followed by headache 10.1% (n = 8), fatigue 10.1% (n = 8), dizziness 7.6% (n = 6), diarrhoea 7.6% (n = 6) and somnolence 6.3% (n = 5) [19] . Similarly, in Noachtar and colleagues trial, headache is reported as the most common adverse event but occurring more frequently in this trial [30] , 21.6% of levetiracetam treated patients (n = 13) [30] .
Notably, psychiatric effects were the most common drug related adverse effect occurring in 22.8% (n = 18) patients in levetiracetam treatment group compared to 14.3% (n = 12) patients in the placebo group [19] . Serious adverse effects resulting in hospitalization or disability were reported in three levetiracetam patients 3.8% (n = 3) compared with 9.5% (n = 8) patients in the placebo group. One case each of aggression, depression and suicide attempt were reported in the levetiracetam group and two cases in placebo [19] . Similarly, there were three cases of depression and two cases of nervousness in the Noachtar trial requiring discontinuation in three patients in the levetiracetam group due to hypersomnia, agitation, depression, anxiety and insomnia [30] .
Discussion
To the best of our knowledge this systematic review is the first to evaluate AED drug trials for drug resistant patients with IGE. From the results obtained in this review it is possible to draw a few discussion points based on the outcome measures defined.
Primary outcome
The primary outcome of this SR was !50% seizure reduction. Seven trials demonstrated a !50% reduction in seizures [19, 20, 21, 22, 23, 28, 30] . Forest plot 1 presented a meta-analysis of included trials. The overall effect in terms of RR was 1.84, CI 1.50-2.13. This was statistically significant (p = <0.00001) with a narrow CI implying that overall this meta-analysis has reasonable power to detect an effect. This suggests that more patients in the drug treatment groups experienced a !50% reduction in seizures compared to placebo. The levetiracetam trial weighed the greatest, followed by perampanel trial. This indicates that these trials provided more information and are more likely to be closer to the true effect. The perampanel trial had a !50% reduction in PGTC seizures and this was statistically significant (p = 0.003) [23] . This trial however, had a short treatment duration of only 17 weeks compared to 24 weeks in the levetiracetam trial. This is short to demonstrate long-term efficacy and safety of the drug.
Patients in the perampanel trial had a definite diagnosis of IGE. Patients who were not certain of a diagnosis or who were not classified were not entered in the trial. This favours the perampanel trial [23] over other trials including the levetiracetam study [19] . There was no standardisation of diagnosis between the recruiting centres; 3-5 Hz spike and wave was seen in only 129 of the 164 patients, with only a confirmed diagnosis in 158 patients [19] . Similarly, in the study of lamotrigine, inclusion criteria may not have been adhered to as some participants had normal EEG's (n = 39) [21] . There is evidence of that some seizures experienced by the included patients were not typical of IGE [19, 20, 21, 28, 29] . Most trials can have pitfalls in terms of seizure classification. Specific clinical and EEG criteria exist for absence and myoclonic seizures. However, in trials of drug resistant patients, typical and atypical absences and idiopathic and symptomatic myoclonic seizures may be misread. Similarly, if strict criteria are not used then trials investigating GTC seizures can become contaminated with patients who have secondary generalised seizures. This can all result in misinterpretation of results. Despite this, the combined analysis of the lamotrigine trials presented a significant statistical difference (SSD) between the two groups in the studies (p < 0.00001). With a narrow CI, this demonstrates that there is an increased likelihood of patients in the lamotrigine group experiencing a !50% reduction in seizures. Encouragingly, this significant seizure response of lamotrigine XR was evident at day 8 of randomisation [22] .
The first paediatric only data from a placebo controlled trial was reported [24] . However, they did not present findings for !50% reduction in PGTC seizures in children and adolescents which was one of their outcomes. This report is a post hoc analysis of the paediatric population in a bigger trial. It comes with its limitations as the trial was not powered for this subgroup analysis. Nevertheless, the percentage reduction of PGTC seizures among children who received lamotrigine was significant and not likely due to chance (p = 0.044) [24] . Both topiramate trials demonstrated that topiramate resulted in !50% reduction from baseline seizures in average monthly PGTC seizure frequency [20, 28] . This was statistically significant (p = 0.003) [20] however with a wide CI (1.43-5.56). Therefore, estimates of effect size will be imprecise. The open label experience of topiramate also had a small sample size therefore estimates are imprecise [28] . In addition, both of these studies demonstrated difficulties in obtaining reliable counts of absence and myoclonic seizures from patient diaries. This will result in subjectivity to data retrieved.
Secondary outcomes
Seizure freedom
The meta-analysis demonstrated a SSD of seizure freedom occurring in the AED treatment group compared to placebo with an overall effect in terms of RR of 2.66. The perampanel trial had the greatest weight (22.8%) [23] , rating closer to the 'true effect'. This trial had encouraging findings which were statistically significant (p = 0.01) [23] . This is noteworthy as patients had more drug resistant seizures. Patients were receiving up to three concomitant AED's, some of which were analysed in this meta-analysis and are recommended for PGTC seizures; notably, lamotrigine (39.3%), levetiracetam (31.3%), sodium valproate (33.7%) and topiramate (15.3%). Both levetiracetam trials demonstrated seizure freedom and were statistically significant in the subgroup sensitivity analysis (p < 0.0001). Both trials were multicentre, similar in design and both achieved better seizure control in the levetiracetam group compared to placebo group. This is the first randomised controlled trial investigating the efficacy of adjunctive levetiracetam for patients with myoclonic seizures [30] . The majority of patients in this trial had a diagnosis of juvenile myoclonic epilepsy 93.4%, (n = 8), seven of which were in the levetiracetam group [30] . Anti myoclonic effect was evident during the first two weeks of treatment at 1000 mg/day and this continued over the twelve week evaluation period [30] . Again syndrome diagnosis was not standardised between recruiting centres in both trials which may introduce bias. However, all the investigators based their diagnosis on clinical and EEG characteristics in accordance with ILAE classification.
The topiramate trials demonstrated seizure freedom however, this was not statistically significant (p = 0.24) [20] . Similarly, lamotrigine presented seizure freedom findings but this was not significant (p = 0.61). The small sample size in both these trials may reflect these findings [20, 21] . Nevertheless, the sensitivity analysis overall was significant (p = 0.00001). This implies that more patients treated with lamotrigine are likely to achieve seizure freedom compared with placebo [21, 22, 24] .
The majority of the included studies investigated PGTC seizures, but not primarily. Other seizures included were myoclonic, absence, clonic, tonic, atonic seizures. Data for efficacy of 'all generalised seizures' was presented but not for the individual seizure type. A total of 50% and 40% of patients had absence and myoclonic seizures respectively in the perampanel study and demonstrated a median percent change in all seizures in the perampanel group (p = 0.0018) [23] . The levetiracetam trial reported seizure freedom in all seizure types (absence and myoclonic seizures), 15.2% (n = 12) versus 6% (n = 5) placebo during the treatment phase but again data is not shown individually. The levetiracetam trial was not designed to assess the efficacy of other seizures but there was no deterioration in other seizures (absence or GTC seizures) [30] . There was no evidence of deterioration of other seizures types and no one withdrew prematurely due to increase frequency of myoclonic seizures [21] . Two trials looked at all generalised seizures [28, 29] . Four of the five of the patients with absence seizures had a !50% reduction and three became seizure free [28] . One person had !50% reduction in myoclonic seizures however the other remaining person with myoclonic seizures worsened [28] . These findings are noteworthy although, as it represents a small patient group; should be cautiously interpreted.
Adverse events
The trials included did show significant findings but they were also associated with adverse events. The perampanel trial had one of the highest percentages of adverse effects of all the trials; 82.7% of patients (n = 67) [23] . It is demonstrated in forest plot 12 that dizziness is more likely to occur in perampanel treated patients than placebo (p = 0.0003). Perampanel was discontinued in 11.1% of perampanel treated patients (n = 9). Five of these patients discontinued treatment due to psychiatric disorders including one case of suicidal ideation. This is previously reported in the phase III extension study of perampanel which included twelve hundred patients [37] . Six cases of suicidal ideation were reported, four of which required hospitalization [37] . There was one case of SUDEP in the placebo group but this was not thought to be AED related [23] .
Included trials adopted various ways of recording adverse effects which may explain some variability in studies. Without the use of a standardised means of recording adverse events there is inconsistency in categorising and recording adverse effects. Three studies involving lamotrigine reported adverse effects. In two of the lamotrigine trials the rates were similar for dizziness, somnolence and nausea [21, 22] and in each of these studies there was one withdrawal each in the lamotrigine groups due to non serious rash. It was considered in both studies that the rash was due to the study medication. Conversely, in the subgroup analysis of children, headache was the most common adverse event and there were no reports of rash. Based on data obtained, this also represents a relative risk, or increased risk of 2.21 (95% CI 0.72-6.78) of such adverse events (dizziness, nausea, somnolence) occurring in the lamotrigine group compared to the placebo group [21] .
Levetiracetam was well tolerated in the included studies [19, 30] . Headache was one of the most common adverse effects in both studies, with variable rates ranging from 10.1%-21.6%. However, rates of headache were higher in the placebo groups. It is worth mentioning that the combined analysis of headache experienced by these levetiracetam treated patients was not significant (p = 0.47). Of note, psychiatric disorders were the most common drug related adverse effect in the levetiracetam group 22.8% (n = 18) [19] . In addition, serious adverse effects including one case each of aggression, suicide attempt and depression were reported in the levetiracetam group and were considered to be related to the study drug. Similarly, in the other levetiracetam trial in the SR, three levetiracetam patients discontinued the drug due to adverse events including depression, anxiety and agitation [30] . Nevertheless only 1.3% (n = 1) of patients withdrew due to side effects compared to 4.85% (n = 4) placebo treated patients [19] . This is consistent with tolerability profile in other studies reported for adjunctive levetiracetam in patients with partial onset seizures [38, 39] .
The most common side effects experienced in the topiramate trials affected the central nervous system including somnolence, fatigue, difficulty with memory and headache. This adverse effect profile in this topiramate trial is consistent with that seen in other topiramate studies [40] . A total of 15% of patients each reported anorexia and weight loss in the topiramate group, resulting in one withdrawal [20] , however this was not statistically significant (p = 0.08).
Methodological issues in trials
All trials were randomised placebo controlled trials where the placebo arm continued their baseline AED's throughout the trial except for one study where concomitant AED was withdrawn or dosage reduced during the open label topiramate treatment [28] . There were however methodological issues with the trials included. In this SR there was no explicit report of methods of randomisation used to generate allocation sequence in four of the studies [21, 22, 28, 29] . Concealment prevents foreknowledge of the forthcoming allocations from care providers, researchers and patients ensuring researchers will not be able to alter it to benefit the intervention [35] . None of the trials included described the method of allocation concealment. This introduces a risk of selection bias within all the studies.
In terms of performance bias, blinding of participants and personnel was evident in four studies [19, 20, 23, 30] . Blinding was unclear in the remainder of the studies with two of these reported as blinded however no actual description of the blinding process was given [24, 29] . Blinding of outcome assessment was unclear in six of the remaining studies [21, 22, 24, 28, 29, 30] . This perhaps introduces detection bias as outcomes assessed were subjective if participants and researchers were not blinded to group allocation.
Incomplete outcome data refers to missing data due to withdrawals from treatment and losses to follow-up [41] . ITT analysis requires that data from all patients is analysed regardless of whether they complied, withdrew or changed their intervention group [41] . Five of the studies reported losses to follow up [19, 20, 21, 22, 23] . Biton and colleagues report losses of sixteen lamotrigine subjects and fourteen placebo subjects [21] . It is unclear how these participants were handled in the efficacy analysis, given that all subjects who were given at least one dose of study medication and were included it is likely that the last observation carried forward was used.
Two of the trials did not report all outcomes, 50% or greater reduction in PGTC seizure frequency which represents reporting bias in these studies [24, 29] . A high placebo response rate was evident in a number of the studies [19, 20, 21, 24] . This high placebo rate in this type of trial on patients with PGTC seizures in IGE may not be unexpected due to possible changes in lifestyle while enrolled in a trial, for example, sleep deprivation, alcohol consumption and improved compliance.
Conclusions of this meta-analysis
This meta-analysis systematically and methodically presented on all the steps necessary to conduct a SR of AED drug treatment options for drug resistant patients with IGE. A thorough search strategy was implemented and can be replicated consequently. Methodological issues in the studies included were mostly associated with risk of bias and difference between recruited populations in the trials in relation to diagnosis of IGE. Nine randomised controlled trials met the inclusion criteria and comprised of data from 921 patients. In relation to outcome measures analysed in this meta-analysis it is possible to conclude that all AED's analysed, except for gabapentin, prove efficacy for drug resistant IGE. This meta-analysis illustrates that eight trials demonstrated efficacy for patients with IGE. Seven of the trials demonstrated efficacy of adjunctive AED with regard to 50% reduction in seizures and eight trials showed seizure freedom. Adverse events profile of AED is noteworthy but is consistent with other studies of these treatment options. The largest sampling was in two studies [19, 23] and both of which had significant reductions in seizures, p = 0.003 and p = 0.0007 respectively. Four of the studies had small sample sizes therefore making it difficult to detect any true differences in outcomes between groups [20, 24, 28, 29] .
This meta-analysis has its limitations. Owing to one language known by the writer, it focused on studies in English language only. This introduces language bias as studies in other languages may have produced more evidence towards the review.
Only nine trials were retrieved during a systematic search of databases which indicates how under investigated this population is. Reasons for paucity of trials are multifactorial. It is broadly acknowledged that randomised controlled trials are the most reliable form of evidence of the effect of medical treatments that informs clinicians practice. However, publication bias is a concern, since trials that produce positive results are more likely to be published than ones that have negative findings. Trials also frequently differ in their methodology, quality and often lack uniformity, for example seizure or epilepsy classification and outcome measures. Systematic reviews have their own limitations. They can only present on primary research so cannot improve poor research. Epilepsy is a chronic condition; most trials are only 11-20 weeks duration therefore too short to inform on the longer term effects of the drug. Moreover, outcomes such as !50% reduction in seizure frequency have little clinical significance and are difficult to put into perspective when making clinical decisions at the bedside.
However, despite that, this systematic review has offered answers to the research question and it has provided a critical and analytical synthesis of the research available on the topic. The meta-analysis increased the statistical power of the SR. It enabled the author to investigate differences between studies and groups of studies, resolving conflicts. This systematic review has found evidence of efficacy and tolerability of investigated AED in IGE Perampanel is a newly licensed drug for patients with IGE and is an exciting new addition for treatment of this patient cohort. New drug development is required for patients with IGE, as are clinical trials of specific epilepsy syndromes. This meta-analysis has highlighted gaps in the literature and our knowledge and will inform future trials. It is clear that additional adequately powered studies, with long term follow up, need to be conducted to unequivocally establish the long term efficacy and tolerability of AED's for patients with drug resistant IGE.
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